How cells adapt to oncogenic transformation-associated cellular stress and become fully transformed is still unknown. Here we identified a novel GGCT-regulated glutathione (GSH)-reactive oxygen species (ROS) metabolic pathway in oncogenic stress alleviation. We identified GGCT as a target of oncogenic Ras and that it is required for oncogenic Ras-induced primary mouse cell proliferation and transformation and in vivo lung cancer formation in the LSL-Kras G12D mouse model. However, GGCT deficiency is compatible with normal mouse development, suggesting that GGCT can be a cancer-specific therapeutic target. Genetically amplified GGCT locus further supports the oncogenic driving function of GGCT. In summary, our study not only identifies an oncogenic function of GGCT but also identifies a novel regulator of GSH metabolism, with implications for further understanding of oncogenic stress and cancer treatment.
INTRODUCTION
Oncogenic transformation in primary somatic cells always leads to cellular stresses, which function as a failsafe mechanism to prevent cancer formation (Luo et al., 2009) . How cells adapt to these oncogenic stresses and become fully transformed is still not very clear. Activating Ras mutations are frequently observed in various cancers; however, these Ras mutants are known to be ''undruggable'' targets (Cox et al., 2014) . Ras downstream targets would be surrogate drug targets for these Ras oncoproteins. Here we identified a novel oncogenic Ras downstream target GGCT, and further characterized GGCT function using mouse models, cancer genomics, and cell biochemical approaches.
GGCT was previously named C7orf24 and was originally identified as a protein up-regulated in bladder urothelial carcinoma (Kageyama et al., 2007) . Subsequent studies indicated that GGCT protein or mRNA is overexpressed in multiple human cancers including breast (Gromov et al., 2010) , lung, esophagus, stomach, bile duct, and uterine cervix cancer (Amano et al., 2012) . In 2008, C7orf24 was identified as g-glutamyl cyclotransferase, and this study renamed C7orf24 as GGCT (Oakley et al., 2008) . The physiological function of this enzyme activity in mammals is not clear. Actually, C7orf24 is not the only protein showing this enzyme activity in mammalian cells (Chi et al., 2014) . g-Glutamyl cyclotransferase catalyzes the following reaction: g-glutamyl-amino acid / 5-oxoproline + amino acid. This enzyme was supposed to participate in glutathione (GSH) homeostasis. Extracellular GSH can be hydrolyzed by membrane-bound g-glutamyl transpeptidase (GGT) to cysteinylglycine and g-glutamyl-amino acid dipeptide (Anderson, 1998; Meister, 1988) . In the cytoplasm, g-glutamyl cyclotransferase cleaves the g-glutamyl-amino acid to give 5-oxoproline and amino acid (Meister, 1974) . However, the function of GGCT (C7orf24) in GSH homeostasis is still unknown. The function of g-glutamyl cyclotransferase enzyme activity in cancer is also unknown; association between this enzyme activity and human cancer has not been reported.
It is already known that protein and mRNA expression of GGCT is up-regulated in multiple types of cancers. However, it is still unknown if GGCT expression up-regulation is simply a by-product of cancer formation or if GGCT up-regulation is required for cancer evolution. The selective accumulation of genetic alterations favoring GGCT up-regulation in cancer, but not normal control tissues, can serve as important cancer genomic evidence supporting the cancer-driving (or oncogenic) function of GGCT.
Here we systematically studied human cancer genome and identified significant GGCT gene amplification in human lung adenocarcinoma (LUAD) . GGCT genomic locus amplification can directly lead to GGCT mRNA up-regulation, suggesting a cancer-driving function of GGCT in human cancer. With newly generated GGCT knockout mouse model and primary cells, we demonstrated a critical role of GGCT in GSH homeostasis and redox balance, critical for primary cell transformation and lung cancer formation, but not normal mouse development.
RESULTS

Chromosome 7p Amplification and Associated Prognosis in Human Lung Adenocarcinoma (LUAD)
Genetic alterations including point mutations and copy number variations in somatic cells are the driving forces for human cancer. Recent cancer genomics efforts, such as The Cancer Genome Atlas (TCGA), enable us to systematically study the genetic alterations in cancer, and many novel oncogenes or tumor suppressors have been identified in this way (Kandoth et al., 2013; Zack et al., 2013) . Here we focused on the copy number alterations of human LUAD, and observed that the short arm of chromosome 7 (7p) is among the top amplified chromosome fragments based on several independent studies (Balsara and Testa, 2002; Lu et al., 2011; Ni et al., 2013; Weir et al., 2007; Wu et al., 2015) ( Figure S1A ). Specifically, 53% of LUAD has amplified 7p (Table S1). In total 389 genes are located in human chromosome 7p region. In addition to LUAD, chromosome 7p is also amplified in other types of human cancers, including colon cancer, glioblastoma, prostate cancer, etc. (Table S1 ).
To investigate whether 7p amplification has an impact on the prognosis of patients with LUAD, we compared the survival curves of patients with LUAD with and without chromosome 7p amplification and observed that patients with LUAD with chromosome 7p amplification were significantly associated with poor prognosis compared with patients without 7p amplification ( Figure S1B ). In early-stage (TNM stage I) LUAD, the effect of 7p amplification on the prognosis is statistically significant, whereas in the late stages (TNM stage III and IV), 7p amplification is not significantly associated with poor patient prognosis (Figure S1C) . This implicates a specific function of 7p amplification in early-stage LUAD.
As 7p is widely amplified in human cancer, some oncogenes located in 7p may be co-amplified and their expression up-regulated consequently. To identify these potential oncogenes in 7p region, we systematically compared the mRNA expression of 389 chromosome 7p genes in normal lung and LUAD samples (Table S2) . GGCT was among the top significantly up-regulated genes when we compare LUAD with normal lung samples. This implies that GGCT may be one of the target genes responsible for 7p amplification-associated cancer. GGCT chromosome locus 7p14.3 was reported to be amplified in lung cancer (Choi et al., 2007) , and in the 7p14.3 region, GGCT is the top significantly expressed up-regulated gene, suggesting that GGCT could also be the target of 7p14.3 amplification in lung cancer.
Stimulation of GGCT Transcription by Activated Ras Signaling
GGCT gene was originally identified when we compared the differentially expressed genes between Kras G12D -expressing and control primary mouse embryonic fibroblasts (MEFs) ( Figure 1A ). When Ras signaling was inhibited with MEK inhibitor trametinib (0.5 mM, 24 h), we observed that GGCT mRNA expression was down-regulated ( Figure 1B) . These observations implicate that GGCT mRNA expression is under the regulation of oncogenic growth signaling. We cloned human GGCT promoter and used it to drive the transcription of luciferase reporter gene. In the presence of trametinib (0.5 mM, 24 h), GGCT promoter activity is also significantly decreased ( Figure 1C ). To further validate the induction of GGCT by Ras signaling, we knocked down KRAS gene in human cancer cells and observed that GGCT transcription is down-regulated ( Figure S2 ). These studies imply that oncogenic Ras signal transcriptionally regulates GGCT expression. When combined with the observation that GGCT locus is amplified in cancer, GGCT transcription regulation by Ras oncogenic signal further supports cancer-related function of GGCT.
GGCT CNV Amplification in Human Cancer
The mRNA and protein expression of GGCT was already known to be up-regulated in various human cancers (Amano et al., 2012; Gromov et al., 2010; Kageyama et al., 2007 Kageyama et al., , 2015 . We checked GGCT mRNA expression in various human cancers and indeed found that the mRNA of GGCT was up-regulated in various cancers compared with each control tissue, and in several cancer types this difference reached statistical significance (Figure 2A ). Based on expression difference, GGCT can be a key gene responsible for chromosome 7p amplification in human LUAD. The copy number of GGCT is systematically investigated in multiple human cancer samples, including lung, prostate, and colon using the TCGA database. Results confirmed GGCT copy number variation (CNV) amplification in multiple human cancers including LUAD iScience 19, 256-266, September 27, 2019 257 ( Figure 2B ). To further evaluate the CNV status of GGCT in cancer, we examined GGCT CNV in LUAD samples by qPCR. In these LUAD samples, GGCT CNV is significantly up-regulated ( Figure 2C ).
Besides human cancer samples, GGCT CNV status was also systematically analyzed in human lung cancer cell lines. Results indicate that GGCT CNV is significantly amplified in human cancer cell lines ( Figure S3A ). We further evaluated GGCT CNV in human cancer cell lines by qPCR, the results confirming the up-regulated GGCT CNV in human lung cancer cell lines ( Figure S3B ). GGCT CNV and mRNA expression show significant correlation in both samples of human patients with cancer ( Figure 2D ) and lung cancer cell lines ( Figure S3C ). This implies that GGCT CNV amplification can directly lead to the up-regulated expression of GGCT mRNA. In addition, GGCT mRNA expression also significantly correlates with GGCT protein level in lung cancer cell lines ( Figure S3D ).
GGCT CNV, mRNA, and LUAD Patient Prognosis
It is known that GGCT mRNA and protein expression are frequently up-regulated in cancers compared with normal control tissues. However, the consequence of GGCT up-regulation in cancer prognosis is still not well studied. Here the prognosis of the patient with lung cancer was evaluated based on GGCT CNV status. Interestingly, in early-stage (TNM stage I) LUAD, patients with amplified GGCT CNV show significantly decreased overall survival ( Figure S4A ), whereas in late-stage LUAD GGCT CNV amplification does not lead to significantly poor prognosis ( Figure S4B ). This result suggests that GGCT CNV amplification may play a specific function in early-stage LUAD. GGCT mRNA expression and LUAD prognosis were also evaluated; GGCT mRNA shows similar trends as GGCT CNV in early-stage LUAD prognosis; the difference does not reach statistical significance based on p < 0.05 ( Figure S4C ). In late-stage LUAD, the prognosis of GGCT mRNA does not show the same trends as in early-stage LUAD ( Figure S4D ). This could implicate a specific function of GGCT mRNA expression in cancer initiation or early-stage cancer progression. Both GGCT mRNA and CNV status do not show significant difference between early-and late-stage LUAD ( Figures S4E and S4F ). And in both stages of LUAD, GGCT mRNA and CNV have similar correlations ( Figures S4G and S4H ). Interestingly, GGCT CNV amplification or mRNA up-regulation shows similar prognosis as chromosome 7p amplification in both early-and late-stage LUAD. This further implicates the critical function of GGCT in cancer-associated 7p amplification. GGCT À/À Mouse Generation and Analysis
No GGCT transgenic or knockout mouse model has ever been reported. To further investigate the function of GGCT, we generated GGCT conditional knockout (GGCT Flox/Flox ) mouse model through embryonic stem (ES) cell targeting and blastocyst injection ( Figure 3A ). We obtained complete GGCT knockout (GGCT À/À ) mouse by crossing GGCT Flox/Flox with EIIa-Cre mouse. The genotyping strategy is described in the Methods section, and genotyping results are shown ( Figure 3B ). The depletion of GGCT protein in GGCT À/À MEFs was further confirmed by western blot analysis with anti-GGCT antibody ( Figure 3C ). GGCT +/À mice are viable and show no apparent phenotypes. When GGCT +/À mice are crossed with GGCT À/À or GGCT +/À mice, the genotype of the pups show Mendialian distribution ( Figure 3D ). Adult GGCT À/À mice do not show difference in body weight when compared with wild-type control mice of similar ages ( Figure S5 ). This indicates that GGCT deficiency is compatible with normal mouse development ( Figure 3E ). (D) Genotyping results of GGCT +/À mouse mated with GGCT +/À mouse and GGCT +/À mouse mated with GGCT À/À mouse. In both cases, the genotype distributions of offspring are in line with Mendel's law, implicating that GGCT deletion is compatible with normal mouse embryonic development.
(E) Representative pictures of two-months-old male and female GGCT +/+ and GGCT À/À mice.
GGCT Depletion Suppresses Primary MEF Transformation and Lung Cancer Formation in Kras G12D Mouse Model
To further investigate the function of GGCT in primary cell proliferation and transformation. We isolated and cultured GGCT À/À and sibling control GGCT +/+ embryonic day 13.5 (E13.5) MEFs from pregnant GGCT +/À female mouse. Early-stage (before passage 4) GGCT À/À MEFs can proliferate albeit at slightly slower speed, whereas late-stage GGCT À/À MEFs show significantly decreased ability in proliferation and completely lose the ability to become automatically transformed during long-passage in vitro culture ( Figure 4A ). GGCT deletion also completely blocked the in vitro proliferation of KRAS G12D -expressing MEFs ( Figure 4A ). GGCT À/À MEFs also show early senescence phenotype ( Figure 4B ). GGCT À/À MEFs can be transformed by large T antigen ( Figure 4A ), which inhibits both Rb and p53 pathways (Ahuja et al., 2005) . In large T antigen-expressing situation, both GGCT À/À and GGCT +/+ MEFs do not show apparent senescent phenotype and can proliferate at similar speed ( Figure 4 ). This indicates that Rb and p53 tumor suppressor may be involved in the growth arrest and senescence phenotypes of GGCT À/À MEFs. Our study demonstrated that GGCT transcription is regulated by Ras signaling (Figure 1 ). To further investigate the in vivo function of GGCT in oncogenic Ras-induced cancer formation, we crossed GGCT À/À mouse with (Lox-Stop-Lox) LSL-Kras G12D mouse model and induced lung cancer formation through intranasal inhalation of Cre recombinase-expressing adenovirus (Jackson et al., 2001) . Significantly decreased tumors are formed in GGCT À/À LSL-Kras G12D mouse compared with LSL-Kras G12D mouse 3 months after adenovirus Cre treatment ( Figures 5A and 5B ). This observation indicates that GGCT is required for efficient lung cancer formation in oncogenic Kras-driving cancer.
Function of GGCT in Alleviating Oncogenic Stress Signaling
To further investigate the molecular mechanism by which GGCT regulates cell proliferation, senescence, and cancer initiation, RNA sequencing (RNA-seq) analysis was performed with primary, Kras G12D -expressing, or large T antigen-transformed GGCT À/À and GGCT +/+ MEFs. The RNA-seq data generated in this study has been deposited in NCBI SRA database with the accession number SRA: PRJNA554607. In both primary and Kras G12D -expressing situations, cell cycle gene signature, specifically Rb-E2F gene signature, is the top different gene signature when comparing GGCT À/À and GGCT +/+ MEFs (Table S3 and Figure S6 ), whereas in large T antigen-transformed situation, this Rb-E2F signature does not appear (Table S3) , and this observation is in line with the fact that large T antigen is able to block Rb tumor suppressor pathway.
GGCT deficiency has no apparent effect on mouse embryonic development and tissue function ( Figure 3 ). In contrast, during Kras G12D oncogenic transformation processes, the accumulated cellular stresses need the presence of GGCT to become adapted, and consequently loss of GGCT significantly impaired cell proliferation in these situations ( Figure 4 ). Cellular stress represented by reactive oxygen species (ROS) is known to be accumulated during oncogene transformation process (Behrend et al., 2003) , and uncontrolled ROS stress can contribute to cell proliferation inhibition and senescence (Pelicano et al., 2004) . We did observe that in GGCT À/À MEFs, ROS level is significantly up-regulated as measured by flow cytometry with ROS indicator carboxy-H2DCFDA ( Figure 6A and B).
GGCT is known to have g-glutamyl cyclotransferase enzyme activity (Oakley et al., 2008) . And in plant, this enzyme activity was reported to participate in GSH homeostasis (Kumar et al., 2015; Paulose et al., 2013) . However, the function of GGCT in GSH metabolism has not been reported. We then checked the GSH level in MEFs and observed that GGCT À/À MEFs have significantly decreased GSH level compared with wildtype sibling control MEFs ( Figure 6C ). This decreased GSH level could contribute to the elevated oxidative stress observed in GGCT À/À MEFs, because GSH is an important antioxidant in cells. Our study thus suggests that GGCT alleviates oncogenic stress by regulating GSH-ROS metabolism. GGCT-deficient MEFs, intracellular L-cysteine level is significantly decreased compared with wild-type control MEFs ( Figure 6D ). Furthermore, the proliferation defect of GGCT À/À MEFs can be rescued by ROS scavenger N-acetylcysteine (NAC) treatment ( Figure 6E ), suggesting that GGCT-regulated GSH-ROS pathway is required for primary cell in vitro proliferation. In summary, our comprehensive cancer genomic and mouse model studies indicate that both oncogenic signal (Ras activation) and chromosomal 7p amplification lead to GGCT expression up-regulation in human cancers. GGCT can help to alleviate cellular stress by regulating GSH-ROS metabolism. In the absence of GGCT, the accumulated cellular stress leads to Rb activation, and consequently cell proliferation arrest and cell senescence ( Figure 6F ).
DISCUSSION
Oncogenic transformation in somatic cells is accompanied by various types of cellular stresses (Solimini et al., 2007) . Inability to handle these cellular stresses will lead to cellular senescence (Braig and Schmitt, 2006; Kuilman et al., 2010) . Oncogenic stress could also be exploited to selectively kill cancer cells but not normal somatic cells through stress sensitization or stress overload (Luo et al., 2009 ). However, how to alleviate these oncogenic transformation-associated cellular stresses is still a key question for cancer research. Here we report that GGCT functions downstream of common oncogenic signal (like Ras) and is required for the alleviation of ROS stress during oncogenic transformation. GGCT could modulate ROS balance by regulating GSH synthesis. GSH is synthesized in the cytoplasm, and the availability of L-cysteine is the key determinant of GSH biosynthesis (Lu, 2013) . Before the identification of ChaC1 as the first cytosolic pathway for GSH degradation in mammalian cells (Kumar et al., 2012) , GSH was thought to be degraded exclusively in the extracellular space by membrane-bound GGT to cysteinylglycine and g-glutamyl-amino acid dipeptide (Ballatori et al., 2009) . One of the best acceptor amino acids for GGT enzymatic reaction is L-cystine (Thompson and Meister, 1976) . In the absence of GGT, intracellular GSH level is down-regulated due to decreased availability of intracellular L-cysteine (Bachhawat and Kaur, 2017; Hanigan, 2014) . Based on our experimental data, GGCT deficiency also leads to decreased intracellular L-cysteine and consequently GSH down-regulation. Thus membrane-bound GGT and cytoplasmic GGCT could be functionally related in GSH homeostasis by recycling L-cysteine. In supporting this interesting hypothesis, GGT expression was also observed to be up-regulated in various human cancers (Hanigan, 2014) .
It has already been reported that GGCT protein or mRNA expression is up-regulated in various cancers, including bladder urothelial carcinoma (Kageyama et al., 2007) , breast cancer (Gromov et al., 2010) , and osteosarcoma (Uejima et al., 2011) . GGCT has also been proposed as a biomarker for cancer (Kageyama et al., 2015) . However, it was still not known if GGCT up-regulation is a simple consequence of cancer progression, or GGCT is selected to be up-regulated during cancer initiation and progression, and thus can have cancer-driving ability.
Bona fide cancer-driving oncogenes are often selected to be amplified through genetic alterations. Here we provide comprehensive and systematic cancer genomics analysis of GGCT gene. Our analysis was based on TCGA, and the results have been verified by performing experiments in human cancer samples or cancer cell lines. We found significant GGCT genetic amplification in human LUAD and other cancers, importantly GGCT, maybe the target gene for chromosome 7p or 7p14.3 amplification in cancer. The amplification of GGCT CNV in LUAD compared with normal lung tissue suggests a selection pressure on GGCT amplification during LUAD initiation or progression. CNV amplification directly leads to GGCT mRNA and protein up-regulation, implicating a potential oncogenic role of GGCT in LUAD.
In early-stage LUAD, GGCT CNV up-regulation is associated with significantly decreased patient prognosis, whereas in late stage of LUAD, the prognosis of patients with GGCT CNV amplification is not significantly decreased compared with patients without GGCT CNV amplification. Similarly, the prognosis of GGCT mRNA expression shows similar trends as GGCT CNV. In early-stage cancer, GGCT up-regulation makes a difference in patient prognosis, meaning a specific function of GGCT in early-stage cancer, probably in cancer initiation. Our in vitro cell culture experiments support the critical function of GGCT in primary cell transformation. And these data are in line with the cancer genomic analysis data, because somatic cell tumorigenic transformation is usually the initial step in cancer progression.
Here we also reported the generation of the first GGCT knockout mouse model. GGCT deficiency is compatible with normal mouse development and tissue function, but it is required for primary MEFs' in vitro growth and transformation. GGCT is transcriptionally regulated by oncogenic Ras signal, and in oncogenic Ras-expressing MEFs, GGCT loss strongly blocked cell proliferation. More importantly, using a LSL-Kras G12D lung cancer mouse model, we demonstrated a critical role of GGCT in oncogenic Rasinduced in vivo tumorigenesis. These data suggested that GGCT could be targeted to specifically block cancer cell growth, and at the same time to not interrupt normal tissue function.
In summary, here we provide human cancer genomic evidence supporting the oncogenic function of GGCT. We identify GGCT as a downstream target of oncogenic Ras signaling, and that it functions as oncogenic stress alleviator by regulating GSH-ROS metabolism. GGCT À/À mouse show normal development; however, GGCT deficiency inhibits cancer cell proliferation and primary cell transformation and reduces lung cancer formation in Kras G12D mouse model. These observations and mechanism study suggest that the selectively amplified GGCT in cancer cells can be a therapeutic target for cancer treatment. Furthermore, the newly identified GSH regulator will have implications for understanding GSH homeostasis and oncogenic stress alleviation.
Limitations of the Study
There are several limitations for this study. First, the detailed mechanism by which GGCT regulates GSH synthesis is not clear. The role of g-glutamyl cyclotransferase enzyme activity in this function is also not clear. In addition, the molecular link between GSH-ROS metabolism and cell transformation is still unknown, and this requires further study. Table S3 . Differentially expressed gene sets between GGCT -/and GGCT +/+ MEFs in primary, KRAS G12D expression and large T antigen transformed situations, Related to Figure 4 . For immunofluorescence staining, the cells was not stained with FLAG antibody, and no background signals can be detected.
TRANSPARENT METHODS
Antibodies and reagents
Anti-GGCT antibody (ab198503, Abcam), Anti--actin antibody (AC-15, Sigma), was used for western blot (WB); Anti-FLAG tag antibody (M2, Sigma), Anti-AIF (D39D2, Cell signaling) antibody (C5C9, Cell signaling), Anti-EEA1 antibody (C45B10, Cell signaling), Anti-LAMP1 antibody (D2D11, Cell signaling), Anti-Calnexin antibody (C5C9, Cell signaling), Anti-RCAS1 antibody (D2B6N, Cell signaling) was used for immunofluorescence; Trametinib (Cayman) was used to inhibit MEK signaling, Carboxy-H2DCFDA (ENZO) was used to measure intracellular ROS level.
Human GGCT promoter cloning and luciferase reporter assay
Human GGCT promoter containing 677-bp upstream of the transcription start site was amplified from human genomic DNA with the primers. 
shRNA knockdown and qPCR quantification of gene expression
We performed shRNA experiments with lentivirus vector to knockdown KRAS genes in human lung cancer cells. KRAS targeting sequence is "5'ccggcccgttggagctagtggcgtagttcaagagactacgccactagctccaactttttggaaa-3'".
pLKO.1 vectors with KRAS targeting shRNA sequence or control sequence (luciferase targeting) was co-transfected with PSPAX2and pMD2G vectors into 293T cells with Lipo2000 transfection reagent according to the manufacturers' protocol. After 48 h, the culture medium was filtered through a 0.22 m filter to obtain retroviral supernatants. Cells were then infected with the retroviral supernatants and 4 g/ml polybrene, and after 10 h, supernatants were removed and cells were grown with complete growth medium for an additional 24 h. Infected cells were then selected with 1 g/ml puromycin. After four days of puromycin selection, cells were used for qPCR quantification analyses. The was measured experimentally using whole genome microarray at a TCGA genome characterization center. Subsequently, GISTIC2 method was applied using the TCGA FIREHOSE pipeline to produce gene-level copy number estimates. GISTIC2 further thresholded the estimated values to -2,-1,0,1,2, representing homozygous deletion, single copy deletion, diploid normal copy, low-level copy number amplification, or high-level copy number amplification.
Gene copy number detection by qPCR
Genes are mapped onto the human genome coordinates using UCSC xena HUGO probeMap. Of note, gene expression was represented as log2 (x+1) transformed RSEM normalized count unless otherwise specified.
Sample classification strategy
To evaluate the influence of CNV status and gene expression status on LUAD prognosis, GISTIC2 estimated value above 0 (representing diploid normal copy) was defined as amplification, and GISTIC2 estimated value equals to 0 was defined as no amplification. 
GSH, L-Cysteine quantification by Mass-spectrometry
2X10 6 cells were seeded in 10cm dishes. 24 hours later, metabolites were extracted with buffer (80% methanol). Samples were dried in a vacuum concentrator, 200μL extraction liquid (V acetonitrile: V water= 1:1) was added for reconstitution. LC-MS/MS analyses were performed using an UHPLC system (1290, Agilent Technologies) with a UPLC BEH Amide column (1.7μm 2.1*100mm, Waters) coupled to Triple TOF 6600 (Q-TOF, AB Sciex). The Triple TOF mass spectrometer was used for its ability to acquire MS/MS spectra on an information-dependent basis (IDA) during an LC/MS experiment. MS raw data (.d) files were converted to the mzXML format using ProteoWizard, and processed by R package XCMS (version 3.2). The preprocessing results generated a data matrix that consisted of the retention time (RT), masstocharge ratio (m/z) values, and peak intensity. R package CAMERA was used for peak annotation after XCMS data processing. In-house MS2 database was applied in metabolites identification.
MEFs virus infection
Primary MEFs were infected with Kras G12D or Large T expressing retrovirus at passage two. Then selected with puromycin (1 g/ml for Kras G12D retrovirus) or hygromycin (50g/ml for Large T retrovirus) for three days. The surviving cells after drug selection were harvested for downstream analysis.
Intracellular ROS level quantification by flow cytometry
1.5X 10 5 cells were seeded in each 6 well plate. 24 hour later, Carboxy-H2DCFDA probes (10 μM) was added into culture medium, and cells were stained for 30 min at 37°C. Then staining medium was washed away, the cells were trypsinized, re-suspended and filtered as single-cell solution. Flow cytometry analysis was performed in BD LSR Fortessa Machine. FITC/GFP channel signal was measured. Fluorescent signal data quantification was analysis with FlowJo software.
Immunoblot
Cells were lysed in buffer (50mM Tris, pH8.0, 150mM NaCl and 0.5% NP-40).
Protein concentrations of the lysates were measured by Bradford assay. The lysates were then resolved by SDS-PAGE and immunoblotted with the indicated antibodies.
Cell proliferation assay
Cells were seeded in 12-well plates at a density of 10 4 /well, then left to grow for four days. Cells were fixed by paraformaldehyde at each time point, and stained with crystal violet. After extensive washing, crystal violet was re-solubilized in 10% acetic acid and quantified at 595 nm as a relative measure of cell number as described previously (Carnero et al., 2000) . For serial 3T3 cell proliferation assay, 1.5 X 10 5 cells were seeded into 3.5-cm dishes every 3 days. The cell number was counted with hemocytometer.
RNA-seq analysis
RNA were extracted from primary, KRAS G12D or Large T expressing GGCT -/and sibling control GGCT +/+ MEFs using TRIzol Reagent (Invitrogen, Carlsbad, CA,USA) according to the manufacturer's protocol and then the RNA is sets. All RNA-seq data generated in this study has been deposited in NCBI SRA database with the accession number PRJNA554607.
Statistics
The significance of the correlation between GGCT CNV, mRNA with clinicopathological characteristics was determined by Student's t-test and fitted with a linear regression model. The significance of the differences between tumor and normal tissues GGCT mRNA was tested by unpaired student's t-test assuming unequal sample variance. ANOVA analysis was used when comparing expression levels in more than two groups. Overall survival was estimated using the Kaplan-Meier method with log-rank test. All data were primarily processed by R software (https://www.r-project.org/). Some statistical analyses and visualization were performed using the software GraphPad Prism 7.00 unless otherwise specified. Error bars were presented as means ± SD, and p < 0.05 was considered statistically significant.
